Isotopia Molecular Imaging and Seibersdorf Labor GmbH Announce Production Agreement for 177Lu n.c.a.

Isotopia Molecular Imaging and Seibersdorf Labor are pleased to announce that they have entered into an agreement for the production of no-carrier-added Lutetium-177, a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer.

Seibersdorf Labor, a GMP Contract manufacturing of radiopharmaceuticals, a global leader in the development, production and commercialization of radiopharmaceuticals, will produce 177Lu n.c.a in collaboration with Isotopia Molecular Imaging for distribution in Europe.

Isotopia has selected Seibersdorf, located in Austria, following a year-long evaluation process that included the review several proposals from sites across Europe. It was selected due to the high level of expertise on site, the GMP infrastructure and the team’s enthusiasm to manufacture lifesaving radiopharmaceuticals. In addition, the location provides easy and safe land transportation access to the European market.

The production facility is expected to be ready by Q4 2022.

177Lu n.c.a is used in Targeted Radionuclide Therapy in the field of Precision Oncology. By binding n.c.a. Lu-177 isotopes to tumor-specific targeting molecules, the resulting radiopharmaceutical targets the tumor and delivers precise cell-killing radiation that spares normal healthy tissue. Isotopia has developed a reliable and unique GMP method to produce a highly pure form of Lu-177. 177Lu n.c.a contains no Mercury (Hg) and no metastable Lu-177m, therefore there is no need for cost intensive clinical waste management.

Isotopia’s CEO & Co-Founder Dr. Eli Shalom stated: This step supports Isotopia’s global strategy to simplify and shorten the supply route to our customers. We are working intensively to complete our plan to establish a production site in each continent. This, to provide a total solution to pharma companies and hospitals together with labeling services. The production and labeling facility in Seibersdorf Laboratories will be the best solution for Europe, enabling Isotopia to deliver a reliable, flexible, and most important, secure land supply of a broad range of critical medical isotopes to European customers, starting with Lu177 n.c.a. We have found in Seibersdorf the best partner sharing the same vision to save lives”.

Seibersdorf’s CEO, Martina Schwaiger stated: “The new production agreement is an exciting opportunity for our organization and we are pleased to be working with Isotopia Molecular Imaging on this important sector of medical care.”

Isotopia and Seibersdorf intend to expand their partnership to include commercial-scale production of 177Lu n.c.a and labeling services to meet future commercial market demand. In addition, both companies have also committed to collaborate on the development of GMP manufacturing processes for other emerging medical isotopes.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to the Central region branch of the Portuguese League Against Cancer
KA Imaging reported a collection of positive metrics to its stakeholders, with revenue four times larger than that of the previous year and a 38% growth in headcount in 2023. The positive trend continues to be observed in Q1 2024.
Isaac Zaworski, President of Sectra advises: "Collaborating across sites and providing efficient radiology workflows are needed to cope with the increasing imaging volumes. This new customer is the 60th healthcare provider to use Sectra in the US Midwest and I'm pleased to be continuing our work in this area. With our local experience as well as our knowledge in providing multi-site solutions for large organizations we will help them on this journey in the best way possible."
MediView notes the system, which has received 510(k) clearance from the U.S. Food and Drug Administration and is currently in clinical use, is intended to be used adjunctively for minimally invasive ultrasound guided needle-based procedures for soft tissue and bone.
The new CT 5300 system is already installed at several European hospitals and has been well-received. “CT 5300 offers CT imaging from head to toe, combined with high-end functionality such as coronary angiography, delivering an extremely broad spectrum of applications, helping us to better manage increased volumes of patients,” said Dr. Hilmar Kühl, Head of Radiology at St. Bernhard-Hospital Kamp-Lintfort, Germany. “With this latest system from Philips, we see an improvement in image quality with Precise Imaging, and for the first time, we can now visualize cardiac anatomy by using Precise Cardiac nearly artifact-free, which is very valuable to help improve cardiac care for our patients.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy